Cargando…

Gene expression‐based drug repurposing to target aging

Aging is the largest risk factor for a variety of noncommunicable diseases. Model organism studies have shown that genetic and chemical perturbations can extend both lifespan and healthspan. Aging is a complex process, with parallel and interacting mechanisms contributing to its aetiology, posing a...

Descripción completa

Detalles Bibliográficos
Autores principales: Dönertaş, Handan Melike, Fuentealba Valenzuela, Matías, Partridge, Linda, Thornton, Janet M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156541/
https://www.ncbi.nlm.nih.gov/pubmed/29959820
http://dx.doi.org/10.1111/acel.12819
_version_ 1783358126824620032
author Dönertaş, Handan Melike
Fuentealba Valenzuela, Matías
Partridge, Linda
Thornton, Janet M.
author_facet Dönertaş, Handan Melike
Fuentealba Valenzuela, Matías
Partridge, Linda
Thornton, Janet M.
author_sort Dönertaş, Handan Melike
collection PubMed
description Aging is the largest risk factor for a variety of noncommunicable diseases. Model organism studies have shown that genetic and chemical perturbations can extend both lifespan and healthspan. Aging is a complex process, with parallel and interacting mechanisms contributing to its aetiology, posing a challenge for the discovery of new pharmacological candidates to ameliorate its effects. In this study, instead of a target‐centric approach, we adopt a systems level drug repurposing methodology to discover drugs that could combat aging in human brain. Using multiple gene expression data sets from brain tissue, taken from patients of different ages, we first identified the expression changes that characterize aging. Then, we compared these changes in gene expression with drug‐perturbed expression profiles in the Connectivity Map. We thus identified 24 drugs with significantly associated changes. Some of these drugs may function as antiaging drugs by reversing the detrimental changes that occur during aging, others by mimicking the cellular defence mechanisms. The drugs that we identified included significant number of already identified prolongevity drugs, indicating that the method can discover de novo drugs that meliorate aging. The approach has the advantages that using data from human brain aging data, it focuses on processes relevant in human aging and that it is unbiased, making it possible to discover new targets for aging studies.
format Online
Article
Text
id pubmed-6156541
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-61565412018-10-01 Gene expression‐based drug repurposing to target aging Dönertaş, Handan Melike Fuentealba Valenzuela, Matías Partridge, Linda Thornton, Janet M. Aging Cell Original Papers Aging is the largest risk factor for a variety of noncommunicable diseases. Model organism studies have shown that genetic and chemical perturbations can extend both lifespan and healthspan. Aging is a complex process, with parallel and interacting mechanisms contributing to its aetiology, posing a challenge for the discovery of new pharmacological candidates to ameliorate its effects. In this study, instead of a target‐centric approach, we adopt a systems level drug repurposing methodology to discover drugs that could combat aging in human brain. Using multiple gene expression data sets from brain tissue, taken from patients of different ages, we first identified the expression changes that characterize aging. Then, we compared these changes in gene expression with drug‐perturbed expression profiles in the Connectivity Map. We thus identified 24 drugs with significantly associated changes. Some of these drugs may function as antiaging drugs by reversing the detrimental changes that occur during aging, others by mimicking the cellular defence mechanisms. The drugs that we identified included significant number of already identified prolongevity drugs, indicating that the method can discover de novo drugs that meliorate aging. The approach has the advantages that using data from human brain aging data, it focuses on processes relevant in human aging and that it is unbiased, making it possible to discover new targets for aging studies. John Wiley and Sons Inc. 2018-08-09 2018-10 /pmc/articles/PMC6156541/ /pubmed/29959820 http://dx.doi.org/10.1111/acel.12819 Text en © 2018 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Papers
Dönertaş, Handan Melike
Fuentealba Valenzuela, Matías
Partridge, Linda
Thornton, Janet M.
Gene expression‐based drug repurposing to target aging
title Gene expression‐based drug repurposing to target aging
title_full Gene expression‐based drug repurposing to target aging
title_fullStr Gene expression‐based drug repurposing to target aging
title_full_unstemmed Gene expression‐based drug repurposing to target aging
title_short Gene expression‐based drug repurposing to target aging
title_sort gene expression‐based drug repurposing to target aging
topic Original Papers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6156541/
https://www.ncbi.nlm.nih.gov/pubmed/29959820
http://dx.doi.org/10.1111/acel.12819
work_keys_str_mv AT donertashandanmelike geneexpressionbaseddrugrepurposingtotargetaging
AT fuentealbavalenzuelamatias geneexpressionbaseddrugrepurposingtotargetaging
AT partridgelinda geneexpressionbaseddrugrepurposingtotargetaging
AT thorntonjanetm geneexpressionbaseddrugrepurposingtotargetaging